Q2 Earnings Season Winds Down: 3 Companies That Broke Records

The 2026 Q2 earnings cycle continues to wind down, with the reporting docket starting to get quiet. The period has been another one of positivity so far, with several companies, including Apple AAPL, EMCOR Group EME, and Johnson & Johnson JNJ, all reporting record-breaking results in one way or another.

Apple Sees Solid Growth

Apple’s results reflected its strongest June-quarter period ever, with quarterly revenue of $109.4 billion growing 16% year-over-year. Adjusted EPS came in at $2.02, growing an even stronger 29% from the year-ago period.

It also reported double-digit revenue growth across iPhone, Mac, and Services, with similar gains in every geographic segment. Its installed base of active devices reached an all-time high across its major product categories, with its overall gross margin seeing a benefit from tariff refunds.

As usual, the iPhone accounted for the mega-cap tech giant’s largest revenue source, with sales coming in at $54.3 billion and growing 21.6% year-over-year.

Image Source: Zacks Investment Research

Though iPhone reflects the greatest portion of sales, the Services category has quickly grown to be another big top line contributor over recent years, with quarterly sales of $30.7 billion reflecting a 12% YoY increase.

Apple’s cash-generating abilities have always been a critical part of investor sentiment surrounding the stock, with it also reporting record operating cash flow for its June-quarter period. The strong cash-generating abilities have allowed shares to trade at a premium, with its dividend payouts pleasing investors looking to obtain top-tier tech exposure paired with paydays.

EMCOR Group Breaks Records

EMCOR similarly posted a double-beat relative to our consensus expectations, with revenues of $5.2 billion reflecting a record and growing nearly 20% YoY. Adjusted EPS of $9.06 reflected a second-quarter-specific record, up 35% from the same period last year.

The company didn’t just post records across headline figures, though, with remaining performance obligations (RPO) of $17.1 billion similarly reflecting an all-time high and surging 44% YoY. The favorable results were capped off with increased sales and earnings guidance, with the stock sporting a favorable Zacks Rank #1 (Strong Buy).

Revenue has shown huge growth over recent years, with the record-high RPO in the release helping keep the overall trajectory bright.

Image Source: Zacks Investment Research

Johnson & Johnson Outperforms

Johnson & Johnson shares have quietly delivered a huge gain in 2026 so far, up nearly 30%. The gain over the last month has similarly shown nice outperformance relative to the S&P 500, with the recent results leading to positive momentum post-earnings.

Sales of $25.3 billion reflected a new quarterly record for the company, growing by a solid 6.6% year-over-year. It also increased both its current fiscal year sales and adjusted EPS guidance, with JNJ now on track to meet its 2026 target of more than $100 billion in annual revenue for the first time in its history.

Image Source: Zacks Investment Research

Bottom Line

The 2026 Q2 earnings season continues to roll along, and results have been positive for many companies, including Apple AAPL, EMCOR Group EME, and Johnson & Johnson JNJ. Not all companies have seen great post-earnings reactions, but the overall earnings landscape remains one of strength.  

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research